<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3453">
  <stage>Registered</stage>
  <submitdate>25/01/2012</submitdate>
  <approvaldate>25/01/2012</approvaldate>
  <nctid>NCT01522898</nctid>
  <trial_identification>
    <studytitle>Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)</studytitle>
    <scientifictitle>Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation</scientifictitle>
    <utrn />
    <trialacronym>CAAN-AF</trialacronym>
    <secondaryid>RAH-HREC-Protocol-#111234</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - AV nodal ablation
Treatment: drugs - Medical Ventricular Rate Control

Active Comparator: Medical Rate Control - Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.

Experimental: AV nodal ablation - AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.


Treatment: surgery: AV nodal ablation
Percutaneous catheter ablation of the AV node.

Treatment: drugs: Medical Ventricular Rate Control
Ventricular Rate Control with target ventricular rate of 90 beats per minute.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All-cause mortality and non-fatal heart failure events - This is a composite of all-cause mortality and non-fatal heart failure events. All-cause mortality will be determined by a designated clinical events committee.
Heart Failure events will be documented by clinical data from the hospital In CAAN-AF, a subject will be described as having a "Heart Failure Event" when the subject has symptoms and/or signs consistent with congestive heart failure and:
responsive to parenteral diuretic or inotropic support as an outpatient
responsive to oral or parenteral diuretic or inotropic support during an inpatient stay</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality - All-cause mortality will be determined after adjudication committee review of clinical records, and death certificate data.</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)f recruitment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular mortality - Cardiovascular deaths will be classified in terms of suddenness and arrhythmic mechanism according to the Hinkle-Thaler criteria.</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Non-Fatal Heart Failure Events - Heart Failure events will be documented by clinical data from the hospital In CAAN-AF, a subject will be described as having a "Heart Failure Event" when the subject has symptoms and/or signs consistent with congestive heart failure and:
responsive to parenteral diuretic or inotropic support as an outpatient
responsive to oral or parenteral diuretic or inotropic support during an inpatient stay</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6-minute walking distance - 6-minute walking distance will be measured according to standard criteria.</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life - Quality of life as assessed by the Short Form 36 (SF-36) questionnaire and Minnesota Living with Heart Failure Questionnaire</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Unplanned Hospitalization - Unplanned hospital admissions will be assessed by a combination of patient self-report, hospital record and/or treating physician interrogation. The reason, date and duration of hospitalization will be recorded Planned hospitalizations (hospital visits for elective or planned medical interventions) will excluded from this outcome</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ventricular arrhythmias requiring device therapy - Ventricular arrhythmias requiring device therapy will be determined by implantable Cardioverter Defibrillator (ICD) interrogation records and clinical records. At each site, the number, duration and type (VT/VF) of device recorded arrhythmias will be recorded, as well as the need for device therapy (anti-tachycardia pacing and/or ICD shocks).</outcome>
      <timepoint>Final-analysis at completion of recruitment and follow-up period (minimum 2 year follow-up)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age = 18 years old

          -  Persistent (= 1 month) or permanent atrial fibrillation. Persistent AF will be where
             obtaining and maintaining sinus rhythm is deemed either not worthwhile, or to be
             ineffective in the long term, or where both the patient and physician accept the
             presence of AF, where rhythm control intervention is, by definition no longer pursued.
             Permanent AF is defined as atrial fibrillation where sinus rhythm cannot be restored.

          -  NYHA class II , III or ambulatory class IV heart failure

          -  Left Ventricular Ejection Fraction (LVEF) = 35% by objective criteria such as
             echocardiography, or cardiac MRI

          -  QRS duration on 12-lead ECG = 120ms

          -  Able and willing to comply with all pre-, post- and follow-up testing and
             requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  age &lt; 18 years

          -  pregnancy

          -  previous AV nodal ablation

          -  Second or third degree AV block

          -  Inability to provide informed consent

          -  life expectancy less than 24 months due to co-morbid illness other than heart failure
             erg cancer, end-stage renal disease, liver failure

          -  Paroxysmal Atrial Fibrillation that self terminates within 7 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>590</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Canberra</hospital>
    <hospital>Concord Hospital - Concord</hospital>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Royal Brisbane Hospital - Brisbane</hospital>
    <hospital>Prince Charles Hospital - Chermside</hospital>
    <hospital>Townsville Hospital and Health Service - Douglas</hospital>
    <hospital>Gold Coast University Hospital - Southport</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Lyell McEwin Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>Northern Hospital - Epping</hospital>
    <hospital>Geelong Hospital - Geelong</hospital>
    <hospital>Austin Hospital - Heidelburg</hospital>
    <hospital>Melbourne Private Hospital - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2605 - Canberra</postcode>
    <postcode> - Concord</postcode>
    <postcode>2305 - New Lambton</postcode>
    <postcode>2065 - Sydney</postcode>
    <postcode> - Sydney</postcode>
    <postcode>4209 - Brisbane</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>4213 - Southport</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5112 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode> - Epping</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3084 - Heidelburg</postcode>
    <postcode> - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Perth</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Martinistr. 52 Geb√§ude Ost 50, 8. OG, Raum 842</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Bay of Plenty</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Adelaide</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Medtronic</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>St. Jude Medical</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Boston Scientific Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Cardiac resynchronization therapy (CRT) is a treatment for heart failure in patients who also
      suffer from ventricular dyssynchrony, a form of uncoordinated contraction of the ventricle
      (lower pumping chamber of the heart). In the past decade, CRT has become an established
      treatment for heart failure patients who are in normal rhythm, called sinus rhythm. An
      important subset of heart failure patients are those with atrial fibrillation (AF), who make
      up around 1 in 4 HF patients, and are over-represented amongst HF patients with more advanced
      symptoms. In heart failure patients with AF, CRT has proven not to be as effective as in
      sinus rhythm, due to competition between beats generated by the CRT device and beats
      conducted from the heart's own electrical conduction system. In the current study, we aim to
      test the hypothesis that ablating the AV node, which controls electrical conduction from the
      heart's atria (top chamber) to its ventricles (lower chambers), will improve survival and
      heart failure symptoms in CRT patients with co-existent AF. The results are important,
      because they will provide a way of passing on the benefits of CRT, such as improved survival,
      less heart failure symptoms, and better quality of life, to heart failure patients who also
      suffer from AF.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01522898</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prashanthan Sanders, MBBS PhD</name>
      <address>University of Adelaide</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Prashanthan Sanders, MBBS PhD</name>
      <address />
      <phone>+61-8-8222-2723</phone>
      <fax />
      <email>prash.sanders@adelaide.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>